Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px
Document › Details

Novacyt S.A.. (4/6/17). "Press Release: Novacyt Announces Bond Issue". Paris & Cambridge.

Organisations Organisation Novacyt S.A. (Alternext: ALNOV)
  Group Novacyt (Group)
  Organisation 2 Alternative Investment Market (AIM) (London)
  Group London Stock Exchange (LSE)
Products Product molecular diagnostics
  Product 2 investment banking
Person Person Mullis, Graham (Novacyt 201409 CEO before Lab21 CEO)
     


Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces the Company has issued a convertible bond in the amount of €1,500,000 through the issuance of 1,500,000 bonds which are convertible into shares with a nominal value of €1.00 each ("OC17VATEL") in favour of FCPI Dividends Plus No 4 fund and FCPI Dividends Plus No 5 fund. On March 31, 2016, the Company recorded the subscription of these 1,500,000 OC17VATEL.

These OC17VATELs were issued in a single tranche with a maturity of 3 years and an annual interest rate of 7.9% and a non-conversion premium paid in arrears of 0.1%. This amount has been allocated to Novacyt SA. The OC17VATEL are convertible only in the event of non-compliance by the Company with its repayment obligations. Only then can the conversion be triggered by holder of the bonds. The conversion parity being 1.25 new shares of the Company for an OC17VATEL.

- End –


About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NovaPrep® and molecular platform, genesig® Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

International
Brett Pollard / Victoria Foster Mitchell
FTI Consulting
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

France
Arnaud de Cheffontaines / Astrid Villette
FTI Consulting
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

NOVACYT
Graham Mullis
Chief Executive Officer
+44 (0)7901 514 121
graham.mullis@novacyt.com

   
Record changed: 2017-07-23

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Novacyt (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px